



TECH DATA SHEET

REPORTER VIRUS PARTICLES

DESCRIPTION

Product	RVP-1707L, SARS-CoV-2 Reporter Virus Particles (RVPs)
Lot	CL-933.8A
Strain	NB.1.8.1 (OMICRON)
Reporter	<i>Renilla</i> Luciferase
Size	1.0 mL/vial
Packaging	20% FBS/DMEM
Recommended Input	2.5uL per well (96-well plate) for a S:B $\geq$ 200*
Mycoplasma Test	Negative
Expiration Date	July 2028

SAFETY & HANDLING

Shipping	Shipped on dry ice
Stability and Storage	Store at $\leq -80^{\circ}\text{C}$ upon receipt

* Determined in the 293T-ACE2 stable cell line. Signal-to-background values can vary depending on instrument make, model, and/or calibration.



SARS-CoV-2 RVPs are used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV-2. RVPs display antigenically correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. RVPs are capable of a single round of infection and carry a genome that expresses either a GFP or luciferase optical reporter gene upon infection. RVPs are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene.

RVPs are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so). However, lentiviruses are capable of genomic integration and RVPs are derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment. RVPs are not to be used in humans or in animals raised for food.

Thaw tubes in a 37°C water bath for 3 minutes and place on ice until ready to use. RVPs will appear as a translucent solution. Gently mix prior to use and pulse tube for 3 seconds at high speed in a tabletop microfuge to recover all volume from the tube. Vortexing of RVPs should be avoided. Re-freezing of RVPs is not recommended.

INFECTIVITY & NEUTRALIZATION DATA

SARS-CoV-2 RVPs (Lot # CL-933.8A)



Infectivity and neutralization determined in HEK-293T cells stably over-expressing ACE2 (Cat# C-HA102). Infectivity data represents the average of three independent vials, each tested in quadruplicate.

Neutralization utilized 5 μl of SARS-CoV-2 RVPs in a 384-well plate. *Renilla* luciferase activity measured using the Promega *Renilla*-Glo luciferase assay system (Promega #E2710). Sample luminescence was read using a Perkin-Elmer Envision plate reader.

SIGNAL TO BACKGROUND	
RVP 384-well Input (µl)	Signal: Background
20	7,235
10	3,940
5	2,115
2.5	1,009
1.25	461
0.63	220
0.31	128

Signal to background is calculated using mock infected cells as the negative control value.